Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients

被引:9
|
作者
Conway, Devon S. [1 ]
Planchon, Sarah M. [1 ]
Oh, Se Hong [2 ]
Nakamura, Kunio [3 ]
Thompson, Nicolas R. [4 ]
Sakaie, Ken [5 ]
Ontaneda, Daniel [1 ]
机构
[1] Cleveland Clin, Neurol Inst, Mellen Ctr Multiple Sclerosis Treatment & Res, 9500 Euclid Ave U10, Cleveland, OH 44195 USA
[2] Hankuk Univ Foreign Studies, Dept Biomed Engn, Yongin, South Korea
[3] Cleveland Clin, Dept Biomed Engn, 9500 Euclid Ave, Cleveland, OH 44195 USA
[4] Cleveland Clin, Neurol Inst Ctr Outcomes Res & Evaluat, Dept Quantitat Hlth Sci, 9500 Euclid Ave JJ3, Cleveland, OH 44195 USA
[5] Cleveland Clin, Imaging Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
关键词
Multiple sclerosis; 7T MRI; Fingolimod; Thalamus; Cognitive Performance;
D O I
10.1016/j.msard.2020.102635
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: : Cognitive impairment is common in relapsing-remitting multiple sclerosis (RRMS) and multiple domains are affected, including information processing speed, episodic memory, and executive function. Damage to the thalamus appears to be related to cognitive functioning in MS. Fingolimod is a disease-modifying therapy for RRMS, which has been shown to have a protective effect on thalamic volume. Objective: : To determine the relationship between cognitive measures and the thalamus in fingolimod-treated RRMS patients and healthy controls using ultra high-field magnetic resonance imaging (MRI). Methods: : Fingolimod-treated RRMS and healthy participants were recruited from a single center to undergo neuropsychological testing and 7 tesla MRI. These assessments were performed at baseline, 6 months, and 12 months. The neuropsychological testing included the Brief Visuospatial Memory Test-Revised (BVMTR), the Symbol Digit Modalities Test (SDMT), the Selective Reminding Test (SRT), and the Delis-Kaplan Executive Function System (DKEFS). MRI metrics included thalamic volume, thalamic myelin density, thalamic axon density, T2 lesion volume, brain parenchymal fraction, and cortical thickness. Mixed-effects linear regression was used to determine the relationship between MRI parameters and neuropsychological test performance over time. Rates of change in patients and controls were compared using two-sample t-tests. Results: : We enrolled 15 RRMS patients and 5 healthy controls. Controls performed better than patients at baseline, but this difference was only significant for the letter fluency subtest of the DKEFS and for long-term storage as assessed by the SRT. Thalamic volume and thalamic myelin density were significantly associated with visuospatial (BVMTR) and verbal memory (SRT). Thalamic volume alone was also associated with inhibitory control (Color word interference subtest of the DKEFS) and cognitive flexibility (Number letter switching subtest of the DKEFS), whereas thalamic myelin density alone was associated with semantic knowledge (Verbal fluency subtest of the DKEFS). There were no significant changes in the rates of change in neurometric test performance or MRI metrics between patients and controls from baseline to 6 months and baseline to 12 months. Conclusions: : Thalamic injury is associated with cognitive performance in several domains. Fingolimod-treated RRMS patients evolved similarly to healthy controls over one year with regards to neuropsychological test performance and changes on MRI.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study
    Ticha, Veronika
    Kodym, Roman
    Pocikova, Zuzana
    Kadlecova, Pavla
    CLINICAL DRUG INVESTIGATION, 2017, 37 (02) : 175 - 186
  • [32] Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study
    Veronika Tichá
    Roman Kodým
    Zuzana Počíková
    Pavla Kadlecová
    Clinical Drug Investigation, 2017, 37 : 175 - 186
  • [33] Cognitive interventions to improve cognitive functioning in patients with multiple sclerosis
    Bacon, J.
    Fromm, J.
    Neuhaus, R.
    Herbert, J.
    MULTIPLE SCLEROSIS, 2007, 13 : S232 - S233
  • [34] Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis
    Paolo Preziosa
    Maria A. Rocca
    Gianna C. Riccitelli
    Lucia Moiola
    Loredana Storelli
    Mariaemma Rodegher
    Giancarlo Comi
    Alessio Signori
    Andrea Falini
    Massimo Filippi
    Neurotherapeutics, 2020, 17 : 208 - 217
  • [35] Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis
    Preziosa, Paolo
    Rocca, Maria A.
    Riccitelli, Gianna C.
    Moiola, Lucia
    Storelli, Loredana
    Rodegher, Mariaemma
    Comi, Giancarlo
    Signori, Alessio
    Falini, Andrea
    Filippi, Massimo
    NEUROTHERAPEUTICS, 2020, 17 (01) : 208 - 217
  • [36] Characterisation of lymphocyte subsets in patients with multiple sclerosis treated with oral fingolimod
    D'Souza, M.
    Kappos, L.
    Lindberg, R.
    Mehling, M.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S343 - S343
  • [37] Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients
    Chiarini, M.
    Sottini, A.
    Bertoli, D.
    Serana, F.
    Caimi, L.
    Rasia, S.
    Capra, R.
    Imberti, L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 726 - 734
  • [38] Impact of OCT and visual function in multiple sclerosis patients treated with Fingolimod
    Perez-Velilla, Javier
    Jose Vicente, Maria
    Vilades Palomar, Elisa
    Orduna Hospital, Elvira
    Cordon Ciordia, Beatriz
    Gil-Arribas, Laura
    Ruiz De Gopegui, Erika
    Jesus Rodrigo, Maria
    Satue Palacian, Maria
    Garcia-Martin, Elena
    ACTA OPHTHALMOLOGICA, 2019, 97
  • [39] Cryptococcal meningoencephalitis in multiple sclerosis treated with fingolimod
    Nasir, Moneeb
    Galea, Ian
    Neligan, Aidan
    Chung, Karen
    PRACTICAL NEUROLOGY, 2023, 23 (06) : 512 - 515
  • [40] COGNITIVE FUNCTIONING IN MULTIPLE SCLEROSIS
    JAMBOR, KL
    BRITISH JOURNAL OF PSYCHIATRY, 1969, 115 (524) : 765 - &